Bio-Thera Solutions announced that the EC has approved BAT2206 (ustekinumab), a biosimilar referencing Stelara® following a positive opinion from the EMA's CHMP on June 19, 2025. Gedeon Richter have rights to market BAT2206 in Europe under the brand name USYMRO®. BAT2206 is Bio-Thera's third EC approved product.
"The EC approval of BAT2206 is another significant accomplishment for Bio-Thera as it marks Bio-Thera's third EC approved product" said Shengfeng Li, CEO at Bio-Thera. "Bio-Thera is committed to expanding access for patients in Europe to important treatments through the continued development of our growing biosimilar pipeline of approved products."
Bio-Thera and Gedeon Richter entered into a license and commercialization agreement for USYMRO® (BAT2206) in October of 2024. Under the terms of the agreement, Bio-Thera is responsible for the development and manufacturing of the product, and Gedeon Richter obtained exclusive rights to commercialize the medicine in the EU, the UK and Switzerland and selected other countries.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!